Get started
Author

Şendağ Yaslıkaya

Observed names: Sendag Yaslikaya, Sendag Yaslıkaya, Ş Yaslıkaya, Şendağ YASLIKAYA, Şendağ Yaslikaya
Institution: Cukurova University
ORCID: 0000-0001-5264-8405
Observed ORCID: 0000-0001-5264-8405
OpenAlex ID: A5001274420
Efficacy of first-line CDK 4-6 inhibitors in premenopausal patients with metastatic breast cancer and the effect of dose reduction due to treatment-related neutropenia on efficacy: a Turkish Oncology Group (TOG) study
2024 · Hasan Cagri Yildirim, Caner Kapar, et al. · Journal of Chemotherapy · 10
The Effectiveness of Adjuvant PD-1 Inhibitors in Patients With Surgically Resected Stage III/IV Acral Melanoma
2024 · Haci Arak, Suna Erkiliç, et al. · Journal of Immunotherapy · 9
Can the Pathological Response in Patients with Locally Advanced Gastric Cancer Receiving Neoadjuvant Treatment Be Predicted by the CEA/Albumin and CRP/Albumin Ratios?
2024 · Ertugrul Bayram, Mehmet Mutlu Kidi, et al. · Journal of Clinical Medicine · 7
Efficacy of everolimus plus hormonal treatment after cyclin-dependent kinase inhibitor; real-life experience, A TOG study
2024 · İsmail Beypınar, Hacer Demir, et al. · Breast Cancer Research and Treatment · 5
Comparison of the Efficacy and Safety of 3 Months of CAPOX Followed by 3 Months of Capecitabine and 6 Months of CAPOX/FOLFOX in the Adjuvant Treatment of Low-Risk Stage III Colon Cancer Treated Surgically
2023 · Murat Bardakci, Derya Demirtas Esmer, et al. · Oncology · 3
Clinical Significance of Achieving No Evidence of Disease in HER2-Positive Metastatic Breast Cancer: A Multicenter Study by Turkish Oncology Group (TOG)
2026 · Bengü Dursun, Şendağ Yaslıkaya, et al. · Cancers · 1
PDF
Comparison of Frontline FOLFIRINOX with Fluorouracil-Based and Gemcitabine-Based Chemotherapies in Metastatic Ampullary Adenocarcinoma: A Multicenter Study by the Turkish Oncology Group (TOG)
2025 · Ali Kalem, Tulay Kus, et al. · Journal of Clinical Medicine · 1
PDF
Efficacy of Second-Line Treatments After Atezolizumab and Bevacizumab in Advanced Hepatocellular Carcinoma and Related Prognostic Factors: A Multicenter Study by the Turkish Oncology Group (TOG)
2025 · Nargiz Majidova, Sendag Yaslıkaya, et al. · The Turkish Journal of Gastroenterology · 1
PDF
Avelumab maintenance in patients with metastatic urothelial carcinoma in a real-life expanded-access program (EAP).
2025 · Deniz Tural, Oğuzcan Özkan, et al. · Journal of Clinical Oncology · 1
Prognostic factors and outcomes of adjuvant and first-line metastatic treatments in melanoma a Turkish oncology group study
2025 · Nargiz Majidova, Hacı Arak, et al. · Scientific Reports · 1
PDF
Evaluation of the Impact of Demographic Data and Clinicopathological Risk Factors on Treatment Response and Survival in Patients With Primary Central Nervous System Lymphoma: a Single-center Experience
2024 · Bulut Sat, Şendağ Yaslıkaya, et al. · Hematology Transfusion and Cell Therapy · 1
Comparison of different cyclin-dependent kinase inhibitors and KI-67 levels on survival and toxicity in breast cancer treatment.
2023 · E Bayram, O Selvi, et al. · PubMed · 1
General-purpose and medically adapted large language models versus oncologist consensus for immunotherapy videos
2026 · Şendağ Yaslikaya, Şuheda Ataş İpek, et al. · Frontiers in Public Health
PDF
Pre-Treatment CD44 and CD47 Expression and Pathological Complete Response After Neoadjuvant Therapy in Breast Cancer: An Exploratory Single-Center Study
2026 · Hatice Asoglu, Esra Asarkaya, et al. · International Journal of Molecular Sciences
Prognostic Significance of CD47 and DHX9 in Metastatic Rectal Cancer
2026 · Sendag Yaslikaya, Suheda Atas Ipek, et al. · Medical Sciences
Is There a Tumor Proportion Score Threshold at Which Tumor-Cell PD-L1 Adds Prognostic Information Beyond the International Prognostic Index in Large B-Cell Lymphoma?
2026 · Mehmet Mutlu Kidi, Suheda Atas Ipek, et al. · Diagnostics
Prognostic Value of the Modified Glasgow Prognostic Score in Patients with Metastatic Renal Cell Carcinoma Receiving Nivolumab as Second-Line Therapy: A Multicentre Retrospective Cohort Study
2026 · Sedat Biter, Ertuğrul Bayram, et al. · Medicina
Real-world outcomes of second-line therapy in advanced thymic carcinoma: a multicenter Turkish Oncology Group (TOG) study
2026 · Fatih Kus, Fatih Atalah, et al. · BMC Cancer
EZH2 Expression and Clinical Outcomes in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors: A Real-World Retrospective Cohort Study
2026 · Esra Asarkaya, Hatice Asoglu, et al. · Journal of Clinical Medicine
Quantitative Immunohistochemical Landscapes and Chemoimmunotherapy Outcomes of ASCL1, NEUROD1, POU2F3, and YAP1 in Pure Small-Cell Lung Cancer: A Pilot Study
2026 · Yasemin Aydinalp Camadan, Arzu Demir Ispir, et al. · Journal of Clinical Medicine
Prognostic factors in avelumab maintenance therapy for metastatic urothelial carcinoma
2026 · Caner Kapar, Oğuzcan Özkan, et al. · Immunotherapy
Precision Oncology in Cholangiocarcinoma: Two Fusion-Positive Case Reports and a Literature Review
2026 · Suheda Ataş Ipek, Şendağ Yaslikaya, et al. · Preprints.org
Prognostic Significance of mEASIX, Inflammatory–Nutritional Biomarkers, Metastatic Patterns, and Treatment Characteristics in Metastatic Melanoma: A Multicenter Real-World Cohort Study
2026 · Şuheda Ataş İpek, Şendağ Yaslıkaya, et al. · Research Square
The Impact of PIK3CA Mutations and Inflammation–Nutritional Biomarkers on Pathological Complete Response in HER2-Positive Early Breast Cancer: A Real-World Cohort Study
2026 · Şuheda Ataş İpek, Şendağ Yaslıkaya, et al. · Preprints.org
Real-World Outcomes and Prognostic Factors in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Sorafenib: A Multicenter Study
2026 · Suheda Atas Ipek, Sendag Yaslikaya, et al. · Journal of Clinical Medicine
PDF
Works count: 43
Citation count: 41
H-index: 4
I10-index: 1
Year
Topic
Type